Docoh
Loading...

47 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
, clinical, regulatory filings and approvals and other product development objectives; the pricing and reimbursement of our product candidates … commissions or expense reimbursement payable to our Sales Agent under the terms of the sales agreement, will be approximately $285,000. The remaining sale
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
objectives; the pricing and reimbursement of our product candidates, if approved; the rate and degree of market acceptance of our product candidates … and contribution toward certain civil liabilities, including liabilities under the Securities Act, and to reimbursement for certain expenses. Unless we
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
means activities directed to obtaining pricing and reimbursement approvals, marketing, promoting, Manufacturing commercial supplies of, distributing … performance of the Compound or Product, actual and projected Development, Regulatory Approval, pricing and reimbursement approval, Manufacturing
424B3
PCSA Processa Pharmaceuticals Inc
12 Apr 21
Prospectus supplement
1:44pm
filings and approvals and other product development objectives; the pricing and reimbursement of our product candidates, if approved; the rate and degree
S-3
PCSA Processa Pharmaceuticals Inc
1 Apr 21
Shelf registration
8:00pm
development objectives; the pricing and reimbursement of our product candidates, if approved; the rate and degree of market acceptance of our product
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
and other product development objectives; the pricing and reimbursement of our product candidates, if approved; the rate and degree of market acceptance … , manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. Mergers
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
the provisions of Section 11(a) of the Act and Rule 158 of the Rules and Regulations. (g) Payment and Reimbursement of Expenses. The Company, whether
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
labeling from regulatory authorities; our ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care … coverage or reimbursement or government pricing approvals. If any of our product candidates are approved, but do not achieve an adequate level
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
authorities; our ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including Medicare … the pricing and usage of therapeutics; and the willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
and maintain sufficient third-party coverage or reimbursement from government health care programs, including Medicare and Medicaid, private health insurers … ; and the willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement or government pricing approvals. If any
S-1/A
EX-3.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
, such Indemnitee shall promptly refund such indemnilication payments to the Corporation to the extent of such insurance reimbursement. All determinations
S-1/A
EX-1.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
158 of the Rules and Regulations. (g) Payment and Reimbursement of Expenses. The Company, whether or not the transactions contemplated hereunder
S-1/A
EX-3.2
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
or understanding with any person or entity other than the corporation with respect to any direct or indirect compensation, reimbursement or indemnification
S-1/A
EX-10.13
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
”. Commercialization or Commercialize means activities directed to obtaining pricing and reimbursement approvals, marketing, promoting, Manufacturing commercial … potential, past performance of the Compound or Product, actual and projected Development, Regulatory Approval, pricing and reimbursement approval
S-1/A
EX-10.11
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
to obtaining pricing and reimbursement approvals, marketing, promoting, Manufacturing commercial supplies of, distributing, importing, offering … or Product, actual and projected Development, Regulatory Approval, pricing and reimbursement approval, Manufacturing and Commercialization costs, existing
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
”. Commercialization or Commercialize means activities directed to obtaining pricing and reimbursement approvals, marketing, promoting, Manufacturing commercial supplies … potential, past performance of the Compound or Product, actual and projected Development, Regulatory Approval, pricing and reimbursement approval
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
to obtaining pricing and reimbursement approvals, marketing, promoting, Manufacturing commercial supplies of, distributing, importing, offering for sale … or Product, actual and projected Development, Regulatory Approval, pricing and reimbursement approval, Manufacturing and Commercialization costs, existing
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
or reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payors … -of-pocket in the absence of third-party coverage or reimbursement or government pricing approvals. If any of our product candidates are approved
10-K
2019 FY
PCSA Processa Pharmaceuticals Inc
5 Mar 20
Annual report
7:00pm
and development, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we … prior to obtaining regulatory marketing approval. Coverage and Reimbursement Sales of our products will depend, in part, on the extent to which our